Xiaozhi Yang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
30
Citations
555
Est. group size
—
Recurring co-author estimate
Active years
30
Publishing since 1997
This publication record appears to combine work from multiple distinct research areas, including cancer drug discovery (small-molecule inhibitors targeting proteins like STAT3, PRMT5, and Werner helicase), cryo-EM structural biology, RNA biology (long non-coding RNAs, microRNAs, circular RNAs) in cancer and skin disease, and unrelated topics such as eye-tracking technology, decision-making models, and facial recognition algorithms. Because the topics are so varied and span different scientific disciplines, it is likely that this name corresponds to more than one researcher or that the bibliographic data has mixed records together. Prospective students should verify the specific research focus and lab affiliation directly, as the data does not clearly indicate a single coherent research program.
Publication output has fluctuated over the last decade, rising to a peak of 6 papers in 2021 before settling to a steady average of about 2 papers per year in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract LB460: Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models
Cancer Research · 2026
- Defending Against AI Agents with Webcam Eye Tracking
2026
- Discovery and Mechanism of 16–19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells
ACS Chemical Biology · 2025
- Decomposing economic choices with drift-diffusion models
2024
- Research on MobileNet-based lightweight face recognition algorithm
2023
- A dynamic computational model of gaze and choice in multi-attribute decisions.
Psychological Review · 2022
- Pharmacological inhibition and reversal of pancreatic acinar ductal metaplasia
Cell Death Discovery · 2022
- Cryo-EM structure-based selection of computed ligand poses enables design of MTA-synergic PRMT5 inhibitors of better potency
Communications Biology · 2022
- Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC
Oncogene · 2021
- LLL12B, a small molecule STAT3 inhibitor, induces growth arrest, apoptosis, and enhances cisplatin-mediated cytotoxicity in medulloblastoma cells
Scientific Reports · 2021
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin
PLoS ONE · 2021
- Cryo-EM structures of human PRMT5:MEP50 complex reveal chemical basis for designing high-specificity inhibitors
Microscopy and Microanalysis · 2021
- Cryo-EM Structure-guided Selection of Computed Ligand Poses to Enhance Potency in MTA-synergic Inhibition of Human Protein Arginine Methyltransferase 5
Research Square · 2021
- Webcam-based online eye-tracking for behavioral research
2020
- Abstract A79: A novel small molecule, LLL12B, inhibits STAT3 Phosphorylation and sensitizes ovarian cancer cell to cisplatin and paclitaxel treatment
Clinical Cancer Research · 2020
- Neuro-Oncology×1
- Psychological Review×1
- Frontiers in Immunology×1
- Cell Proliferation×1
- Oncogene×1
- Mireia Guerau‐de‐Arellano
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Bennett D. Elzey
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Chang‐Deng Hu
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Andrew M. Asberry
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Dipankor Chatterjee
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile